Ascletis Pharma Carries Out HKD 2.01 Million Share Buyback; Cumulative Repurchases Climb to 7.49 Million Shares

Bulletin Express06-09

Ascletis Pharma Inc. disclosed via a Next Day Disclosure Return (9 June 2026) that it repurchased an additional 200,000 ordinary shares on 9 June 2026. The on-market purchases were executed at prices between HKD 9.80 and HKD 10.28 per share, for a total consideration of HKD 2.01 million, implying an average purchase price of HKD 10.07 per share.

As at the close of 9 June 2026, the company’s share capital comprised 1.06 billion issued shares (excluding treasury shares), unchanged from the previous day. Treasury shares stood at 7.08 million, reflecting ongoing but not yet cancelled buybacks.

Since the current repurchase mandate was approved on 22 May 2025, Ascletis Pharma has bought back 7.49 million shares, representing 0.78 % of the company’s issued share capital at the date of the mandate. The mandate permits repurchases of up to 96.28 million shares, leaving more than 88 million shares, or about 92 % of the authorised limit, still available.

Pending cancellation, a total of 6.99 million shares repurchased between April 2025 and 9 June 2026 remain in treasury at an aggregate cost reflecting individual transaction prices ranging from HKD 4.85 to HKD 14.58 per share.

Under Hong Kong Stock Exchange rules, Ascletis Pharma is subject to a 30-day moratorium on issuing new shares or selling treasury shares, effective until 9 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189882041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189882041","market":"hk","top_or_hot":-1,"title":"Ascletis Pharma Carries Out HKD 2.01 Million Share Buyback; Cumulative Repurchases Climb to 7.49 Million Shares","media":"Bulletin Express","content":"<p>Ascletis Pharma Inc. disclosed via a Next Day Disclosure Return (9 June 2026) that it repurchased an additional 200,000 ordinary shares on 9 June 2026. The on-market purchases were executed at prices between HKD 9.80 and HKD 10.28 per share, for a total consideration of HKD 2.01 million, implying an average purchase price of HKD 10.07 per share.</p>\n<p>As at the close of 9 June 2026, the company’s share capital comprised 1.06 billion issued shares (excluding treasury shares), unchanged from the previous day. Treasury shares stood at 7.08 million, reflecting ongoing but not yet cancelled buybacks.</p>\n<p>Since the current repurchase mandate was approved on 22 May 2025, Ascletis Pharma has bought back 7.49 million shares, representing 0.78 % of the company’s issued share capital at the date of the mandate. The mandate permits repurchases of up to 96.28 million shares, leaving more than 88 million shares, or about 92 % of the authorised limit, still available.</p>\n<p>Pending cancellation, a total of 6.99 million shares repurchased between April 2025 and 9 June 2026 remain in treasury at an aggregate cost reflecting individual transaction prices ranging from HKD 4.85 to HKD 14.58 per share.</p>\n<p>Under Hong Kong Stock Exchange rules, Ascletis Pharma is subject to a 30-day moratorium on issuing new shares or selling treasury shares, effective until 9 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma Carries Out HKD 2.01 Million Share Buyback; Cumulative Repurchases Climb to 7.49 Million Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma Carries Out HKD 2.01 Million Share Buyback; Cumulative Repurchases Climb to 7.49 Million Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-09 18:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascletis Pharma Inc. disclosed via a Next Day Disclosure Return (9 June 2026) that it repurchased an additional 200,000 ordinary shares on 9 June 2026. The on-market purchases were executed at prices between HKD 9.80 and HKD 10.28 per share, for a total consideration of HKD 2.01 million, implying an average purchase price of HKD 10.07 per share.</p>\n<p>As at the close of 9 June 2026, the company’s share capital comprised 1.06 billion issued shares (excluding treasury shares), unchanged from the previous day. Treasury shares stood at 7.08 million, reflecting ongoing but not yet cancelled buybacks.</p>\n<p>Since the current repurchase mandate was approved on 22 May 2025, Ascletis Pharma has bought back 7.49 million shares, representing 0.78 % of the company’s issued share capital at the date of the mandate. The mandate permits repurchases of up to 96.28 million shares, leaving more than 88 million shares, or about 92 % of the authorised limit, still available.</p>\n<p>Pending cancellation, a total of 6.99 million shares repurchased between April 2025 and 9 June 2026 remain in treasury at an aggregate cost reflecting individual transaction prices ranging from HKD 4.85 to HKD 14.58 per share.</p>\n<p>Under Hong Kong Stock Exchange rules, Ascletis Pharma is subject to a 30-day moratorium on issuing new shares or selling treasury shares, effective until 9 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1189882041","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189882041","pubTimestamp":1781000588,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascletis Pharma Inc. disclosed via a Next Day Disclosure Return (9 June 2026) that it repurchased an additional 200,000 ordinary shares on 9 June 2026. The on-market purchases were executed at prices...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"歌礼制药进行201万港元股份回购；累计回购攀升至749万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"Ascletis Pharma Inc. disclosed via a Next Day Disclosure Return (9 June 2026) that it repurchased an additional 200,000 ordinary shares on 9 June 2026. The on-market purchases were executed at prices between HKD 9.80 and HKD 10.28 per share, for a total consideration of HKD 2.01 million, implying an average purchase price of HKD 10.07 per share.\nAs at the close of 9 June 2026, the company’s share capital comprised 1.06 billion issued shares (excluding treasury shares), unchanged from the previous day. Treasury shares stood at 7.08 million, reflecting ongoing but not yet cancelled buybacks.\nSince the current repurchase mandate was approved on 22 May 2025, Ascletis Pharma has bought back 7.49 million shares, representing 0.78 % of the company’s issued share capital at the date of the mandate. The mandate permits repurchases of up to 96.28 million shares, leaving more than 88 million shares, or about 92 % of the authorised limit, still available.\nPending cancellation, a total of 6.99 million shares repurchased between April 2025 and 9 June 2026 remain in treasury at an aggregate cost reflecting individual transaction prices ranging from HKD 4.85 to HKD 14.58 per share.\nUnder Hong Kong Stock Exchange rules, Ascletis Pharma is subject to a 30-day moratorium on issuing new shares or selling treasury shares, effective until 9 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189882041","isCrawlerRequest":true}